Clinical Trial Update: Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line [Phase 2]

View source ↗

Summary

Phase 2 study of AVE5026 for thrombosis prophylaxis in children with a central venous line was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Venous Catheter-related Thrombosis
• Venous Thromboembolism

Drugs mentioned

• AVE5026

Snippet

Sponsor: Sanofi | Conditions: Thrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL) | Phase 2 | Status: TERMINATED